Long-term outcomes of local resection versus surgical resection for high-risk T1 colorectal cancer: a systematic review and meta-analysis

医学 危险系数 结直肠癌 置信区间 内科学 生存分析 淋巴结 荟萃分析 比例危险模型 肿瘤科 胃肠病学 癌症 外科
作者
Yuxiang Chen,Weina Jing,Mo Chen,Zhu Wang,Junchao Wu,Jinlin Yang,Yang Li,Kai Deng
出处
期刊:Gastrointestinal Endoscopy [Elsevier BV]
卷期号:97 (6): 1016-1030.e14 被引量:19
标识
DOI:10.1016/j.gie.2023.02.027
摘要

Patients with T1 colorectal cancer (CRC) are at high risk for lymph node metastasis and recurrence after local resection (LR) and need surgical resection (SR) for additional lymph node dissection to improve prognosis. However, the net benefits of SR and LR are still unquantified.We conducted a systematic search for studies in which survival analysis among high-risk T1 CRC patients undergoing LR and SR was performed. Overall survival (OS), recurrence-free survival (RFS), and disease-specific survival (DSS) data were extracted. Hazard ratios (HRs) and fitted survival curves for OS, RFS, and DSS were used to estimate the long-term clinical outcomes of patients in the 2 groups.This meta-analysis included 12 studies. Compared with those in the SR group, patients in the LR group had higher risks of death (HR, 2.06; 95% confidence interval [CI], 1.59-2.65), recurrence (HR, 3.51; 95% CI, 2.51-4.93), and cancer-related mortality (HR, 2.31; 95% CI, 1.17-4.54) in the long term. Fitted survival curves for the LR and SR groups revealed the 5-year, 10-year, and 20-year rates for OS (86.3% and 94.5%, 72.9% and 84.4%, and 61.8% and 71.1%), RFS (89.9% and 96.9%, 83.3% and 93.9%, and 29.6% and 90.8%), and DSS (96.7% and 98.3%, 86.9% and 97.1%, and 86.9% and 96.4%). Log-rank tests showed significant differences among all outcomes except 5-year DSS.For high-risk T1 CRC patients, the net benefit of DSS appears to be significant when the observation period exceeds 10 years. A long-term net benefit may exist but may not be applicable to all patients, especially high-risk patients with comorbidities. Therefore, LR may be a reasonable alternative for individualized treatment for some high-risk T1 CRC patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
圆圆滚滚发布了新的文献求助10
1秒前
2秒前
bnjay发布了新的文献求助10
2秒前
Lynn完成签到 ,获得积分10
2秒前
2秒前
qwerxx发布了新的文献求助10
2秒前
Nelson_Foo完成签到,获得积分10
2秒前
4秒前
乐乐应助小羊采纳,获得10
4秒前
zmmouc发布了新的文献求助10
5秒前
Yuejun发布了新的文献求助10
5秒前
5秒前
yuyuyuyuyuyuyu完成签到,获得积分10
6秒前
8秒前
芋圆完成签到 ,获得积分10
8秒前
诸乘风完成签到,获得积分10
9秒前
机智乐菱发布了新的文献求助10
9秒前
KBRS发布了新的文献求助10
10秒前
11秒前
呱呱发布了新的文献求助10
12秒前
路瑶瑶完成签到,获得积分10
14秒前
14秒前
思源应助科研通管家采纳,获得10
15秒前
科目三应助科研通管家采纳,获得10
15秒前
科研通AI2S应助科研通管家采纳,获得30
15秒前
zmmouc完成签到,获得积分10
15秒前
汉堡包应助科研通管家采纳,获得10
15秒前
天天快乐应助科研通管家采纳,获得10
15秒前
深情安青应助科研通管家采纳,获得10
15秒前
隐形曼青应助科研通管家采纳,获得10
15秒前
FashionBoy应助科研通管家采纳,获得10
15秒前
Akim应助科研通管家采纳,获得10
15秒前
打打应助科研通管家采纳,获得10
15秒前
我是老大应助科研通管家采纳,获得10
16秒前
香蕉觅云应助科研通管家采纳,获得10
16秒前
Amu1uu应助科研通管家采纳,获得10
16秒前
汉堡包应助科研通管家采纳,获得10
16秒前
天天快乐应助科研通管家采纳,获得10
16秒前
慕青应助科研通管家采纳,获得10
16秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A new approach to the extrapolation of accelerated life test data 500
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3954525
求助须知:如何正确求助?哪些是违规求助? 3500615
关于积分的说明 11100212
捐赠科研通 3231137
什么是DOI,文献DOI怎么找? 1786269
邀请新用户注册赠送积分活动 869920
科研通“疑难数据库(出版商)”最低求助积分说明 801719